Brain Tumor-Targeting Peptide for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for brain tumors are limited by the blood-brain barrier, making it difficult for most drugs to effectively target brain tumors.
Innovation Solution
A brain tumor targeted molecule is developed, comprising a blood-brain barrier crossing region and a tumor target region, where the blood-brain barrier crossing region includes the peptide sequence TFYGGRPKRNNFLRGIRSRGD, and the tumor target region can include sequences such as CGKRK or ATWLLPPR, allowing the molecule to efficiently cross the blood-brain barrier and target brain tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic drugs are used for brain tumors, then the drugs have limited effectiveness, but the blood-brain barrier prevents most substances from entering the brain
Solution Approach 1:
The patent uses a peptide vector as an intermediary carrier to transport therapeutic drugs across the blood-brain barrier. The peptide sequence TFYGGRPKRNNFLRGIRSRGD acts as a mediator that facilitates drug entry into the brain by interacting with transport mechanisms in the blood-brain barrier, thereby enabling drugs that would otherwise be blocked to reach their target effectively
Solution Approach 2:
The invention creates a composite structure combining the peptide vector with therapeutic drugs. This composite material allows the drug to be delivered through the blood-brain barrier while maintaining its therapeutic function, resolving the contradiction between barrier protection and drug delivery
2Ease of operation
If RGD peptide is used to cross the blood-brain barrier, then the peptide can reach brain tumors, but the ability to specifically target tumor cells must be maintained
Solution Approach 1:
The patent merges two functional peptide sequences into one: the blood-brain barrier crossing sequence TFYGGRPKRNNFLRGIR and the tumor-targeting RGD sequence. This combined peptide simultaneously performs both functions - crossing the blood-brain barrier and specifically binding to integrins on tumor cells, thus resolving the contradiction between barrier penetration and targeting specificity
Solution Approach 2:
The designed peptide vector possesses multiple functions: it can cross the blood-brain barrier, target tumor cells specifically through RGD-integrin interaction, and serve as a carrier for therapeutic drugs. This multi-functionality allows a single molecule to address multiple requirements that would otherwise be in conflict
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The brain tumor targeted molecule effectively crosses the blood-brain barrier and retains its ability to target brain tumors, providing a new platform for both diagnostic imaging and targeted therapy of brain tumors.
Implementation Method 1
based on the idea of receptor-mediated pathway, the receptor pathway mediated by receptor LRP1 can be used to select a skeleton
Implementation Method 2
RGD is a short peptide sequence containing arginine-glycine-aspartic acid (Arg-Gly-Asp), which acts as a recognition site for the interaction of integrins and its ligands
Data Source
AI summary
The present invention related to a brain tumor-targeting peptide, a coding nucleic acid thereof, and a vector and host cell comprising the coding nucleic acid. The targeting peptide linked to a diagnostic marker can be used in brain tumor diagnosis, especially in brain tumor imaging; and the targeting peptide when linked to a therapeutic drug can carry the drug directly to a brain tumor lesion so as to achieve brain tumor treatment.